BR112021020843A2 - Set of heterodimeric precursor polypeptides, heterodimeric polypeptides, methods for generating a heterodimeric polypeptide and for identifying a multispecific heterodimeric polypeptide, multispecific heterodimeric polypeptide, first and second heterodimeric precursor polypeptides - Google Patents

Set of heterodimeric precursor polypeptides, heterodimeric polypeptides, methods for generating a heterodimeric polypeptide and for identifying a multispecific heterodimeric polypeptide, multispecific heterodimeric polypeptide, first and second heterodimeric precursor polypeptides

Info

Publication number
BR112021020843A2
BR112021020843A2 BR112021020843A BR112021020843A BR112021020843A2 BR 112021020843 A2 BR112021020843 A2 BR 112021020843A2 BR 112021020843 A BR112021020843 A BR 112021020843A BR 112021020843 A BR112021020843 A BR 112021020843A BR 112021020843 A2 BR112021020843 A2 BR 112021020843A2
Authority
BR
Brazil
Prior art keywords
heterodimeric
polypeptide
polypeptides
multispecific
precursor
Prior art date
Application number
BR112021020843A
Other languages
Portuguese (pt)
Inventor
Martin Buldun Can
David Zilian
Eike Hoffmann
Guy Georges
Sabine Imhof-Jung
Stefan Dengl
Steffen Dickopf
Ulrich Brinkmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112021020843A2 publication Critical patent/BR112021020843A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

conjunto de polipeptídeos precursores heterodiméricos, polipeptídeos heterodiméricos, métodos para gerar um polipeptídeo heterodimérico e para identificar um polipeptídeo heterodimérico multiespecífico,polipeptídeo heterodimérico multiespecífico, primeiro e segundo polipeptídeo precursor heterodimérico. a presente invenção se refere a um conjunto de polipeptídeos heterodiméricos e seus usos, por exemplo, para gerar ligantes de antígenos multiespecíficos por troca de cadeia polipeptídica.set of heterodimeric precursor polypeptides, heterodimeric polypeptides, methods for generating a heterodimeric polypeptide and for identifying a multispecific heterodimeric polypeptide, multispecific heterodimeric polypeptide, first and second heterodimeric precursor polypeptides. the present invention relates to a set of heterodimeric polypeptides and their uses, for example, to generate multispecific antigen ligands by polypeptide chain exchange.

BR112021020843A 2019-04-25 2020-04-24 Set of heterodimeric precursor polypeptides, heterodimeric polypeptides, methods for generating a heterodimeric polypeptide and for identifying a multispecific heterodimeric polypeptide, multispecific heterodimeric polypeptide, first and second heterodimeric precursor polypeptides BR112021020843A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19171068 2019-04-25
PCT/EP2020/061412 WO2020216878A1 (en) 2019-04-25 2020-04-24 Generation of antibody-derived polypeptides by polypeptide chain exchange

Publications (1)

Publication Number Publication Date
BR112021020843A2 true BR112021020843A2 (en) 2022-02-01

Family

ID=66334197

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020843A BR112021020843A2 (en) 2019-04-25 2020-04-24 Set of heterodimeric precursor polypeptides, heterodimeric polypeptides, methods for generating a heterodimeric polypeptide and for identifying a multispecific heterodimeric polypeptide, multispecific heterodimeric polypeptide, first and second heterodimeric precursor polypeptides

Country Status (12)

Country Link
US (1) US20220033525A1 (en)
EP (1) EP3959244A1 (en)
JP (1) JP2022531128A (en)
KR (1) KR20220005031A (en)
CN (1) CN113728002A (en)
AU (1) AU2020261250A1 (en)
BR (1) BR112021020843A2 (en)
CA (1) CA3132275A1 (en)
IL (1) IL287400A (en)
MX (1) MX2021012871A (en)
TW (1) TW202106714A (en)
WO (1) WO2020216878A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP3227332B1 (en) * 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
IL303518A (en) * 2020-12-10 2023-08-01 Invenra Inc Orthogonal mutations for heterodimerization
AU2022318255A1 (en) 2021-07-27 2024-01-18 Morphosys Ag Combinations of antigen binding molecules

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE69830901T2 (en) 1997-05-02 2006-05-24 Genentech Inc., San Francisco A method for producing multispecific antibodies having heteromultimeric and common components
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
AU2007229698B9 (en) 2006-03-24 2012-11-08 Merck Patent Gmbh Engineered heterodimeric protein domains
JP2009541275A (en) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス Production of bispecific antibodies
PT2235064E (en) 2008-01-07 2016-03-01 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CN102459346B (en) 2009-04-27 2016-10-26 昂考梅德药品有限公司 The method manufacturing heteromultimers molecule
SI2519543T1 (en) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
EP3418306B1 (en) * 2011-10-11 2023-12-06 F. Hoffmann-La Roche AG Improved assembly of bispecific antibodies
CA2859667C (en) 2011-12-20 2022-05-24 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
MX360109B (en) * 2012-04-20 2018-10-23 Merus Nv Methods and means for the production of ig-like molecules.
EA032681B1 (en) * 2012-11-27 2019-07-31 Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн HETERODIMER Fc OF IMMUNOGLOBULIN COMPRISING A CH3 DOMAIN VARIANT FOR FORMING AN ANTIBODY OR A FUSION PROTEIN WITH A HETERODIMERIC Fc AT HIGH EFFICIENCY, METHOD FOR PREPARING AND USING SAME
EP3227332B1 (en) * 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
CN106883297B (en) * 2015-12-16 2019-12-13 苏州康宁杰瑞生物科技有限公司 CH3 domain-based heterodimer molecule, preparation method and application thereof
WO2018016881A1 (en) * 2016-07-19 2018-01-25 (주)아이벤트러스 Bispecific proteins and methods for preparing same
EP3697441B1 (en) * 2017-10-20 2023-06-07 F. Hoffmann-La Roche AG Method for generating multispecific antibodies from monospecific antibodies
CA3078676A1 (en) * 2017-10-30 2019-05-09 F. Hoffmann-La Roche Ag Method for in vivo generation of multispecific antibodies from monospecific antibodies
EP3703821A2 (en) * 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Bispecific 2+1 contorsbodies

Also Published As

Publication number Publication date
JP2022531128A (en) 2022-07-06
KR20220005031A (en) 2022-01-12
CN113728002A (en) 2021-11-30
CA3132275A1 (en) 2020-10-29
WO2020216878A1 (en) 2020-10-29
US20220033525A1 (en) 2022-02-03
AU2020261250A1 (en) 2021-10-14
IL287400A (en) 2021-12-01
EP3959244A1 (en) 2022-03-02
MX2021012871A (en) 2021-11-17
TW202106714A (en) 2021-02-16

Similar Documents

Publication Publication Date Title
BR112021020843A2 (en) Set of heterodimeric precursor polypeptides, heterodimeric polypeptides, methods for generating a heterodimeric polypeptide and for identifying a multispecific heterodimeric polypeptide, multispecific heterodimeric polypeptide, first and second heterodimeric precursor polypeptides
CL2021001686A1 (en) Single Domain Antibody-Based Chimeric Antigen Receptors and Methods of Using Them (Divisional Application No. 201800378)
CL2023001092A1 (en) Agonist molecules binding to the cd28 antigen that act on the tumor
BR112019007288A2 (en) bispecific heterodimeric protein, nucleic acid and expression vector compositions, expression vector, host cell, and methods for producing bispecific heterodimeric protein and for treating cancer in a patient
CO2020001029A2 (en) Polypeptide molecule with enhanced dual specificity
DOP2018000259A (en) BISPECIFIC UNION PROTEINS THAT JOIN AN IMMUNOMODULATORY PROTEIN AND A TUMORAL ANTIGEN
CY1123358T1 (en) AQUEOUS PHARMACEUTICAL FORMULATION CONTAINING ANTI-PD-1 ANTIBODY AVELUMABI
CY1124806T1 (en) ENANTI-CD40 ANTIBODIES AND USES THEREOF
ECSP19050049A (en) ANTI-OX40 ANTIBODIES AND THEIR USES
BR112021016903A2 (en) Administration of biomolecules to pbmcs to modify an immune response
DOP2016000225A (en) ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
CO2018011195A2 (en) Compositions comprising a coformulation of anti-pd-l1 and anti-ctla-4 antibodies
CL2018003515A1 (en) Anti-gitr antibodies and their uses.
CY1124521T1 (en) ANTI-CD19 ANTIBODY PREPARATIONS
BR112018010605A2 (en) beverage nanoemulsions produced by high shear processing
BR112022001207A2 (en) Method of obtaining mitochondria from cells and mitochondria obtained
BR112021016198A2 (en) Anti-il-36r antibody formulations
NI202000087A (en) MONOSPECIFIC AND MULTISPECIFIC ANT-TMEFF2 ANTIBODIES AND THEIR USES
CO2018001599A2 (en) A monoclonal antibody inhibitor of factor xiia
BR112017001004A2 (en) catalyst composition, process for ethylene oligomerization and ethylene oligomerization reaction which produces 1-hexene and 1-octene
AR121461A1 (en) METHODS FOR THE MANUFACTURE OF CELLS EXPRESSING THE CHIMERIC ANTIGEN RECEPTOR
CR20210200A (en) Antibody formulation
BR112021020859A2 (en) Polypeptide assemblies, method for generating a polypeptide, heterodimeric polypeptide, first heterodimeric precursor polypeptide, and second heterodimeric precursor polypeptide
CY1120812T1 (en) SUBSTITUTED DERIVATIVES AZASPIRO (4.5) DECANE
CO2022000748A2 (en) Pyrazolopyrimidine compound, preparation method therefor and its applications